Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    Tysabri | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Tysabri Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: natalizumab
2 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
3 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
4 Recruiting Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Natalizumab
5 Not yet recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
6 Recruiting Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
Condition: Multiple Sclerosis
Intervention: Drug: natalizumab
7 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
8 Recruiting Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Radiation: Diffusion Magnetic Resonance Imaging at 6 months
9 Recruiting Methylprednisolone During the Switch Between Natalizumab and Fingolimod
Condition: Multiple Sclerosis
Interventions: Drug: Methylprednisolone;   Drug: Placebo;   Drug: natalizumab (NTZ);   Drug: fingolimob (FTY)
10 Recruiting Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: biological samples and clinical data
11 Unknown  Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
Conditions: Multiple Sclerosis;   Cognitive Impairment
12 Not yet recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
13 Recruiting Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: mitoxantrone - immunomodulator;   Other: natalizumab
14 Recruiting Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Condition: Multiple Sclerosis
15 Recruiting Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk
Condition: Multiple Sclerosis
16 Unknown  A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Other: MSDX Complex-1 Biomarker test
17 Recruiting Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Condition: Multiple Sclerosis
Interventions: Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
18 Unknown  A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: MSDx Complex-1 Biomarker Test

Indicates status has not been verified in more than two years